Diagnostic testing solutions provider Quidel has obtained marketing approval from the US Food and Drug Administration (FDA) for its Solana respiratory syncytial virus (RSV) + human metapneumovirus (hMPV) Assay for the diagnosis of RSV and/or hMPV infections.

Indicated for use in the Solana instrument, the assay is designed to detect nucleic acids extracted from nasal and nasopharyngeal swabs of patients having signs and symptoms of a respiratory infection.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The assay uses a new Reverse-Transcriptase Helicase-Dependent Amplification (HDA) for the generation of a rapid and accurate test result within 45 minutes.

Quidel president and CEO Douglas Bryant said: “We are pleased to introduce an additional innovative, rapid testing solution that addresses the leading cause of viral respiratory infections in both the young and elderly, RSV and hMPV.

“The easy-to-use molecular test does not require prior RNA extraction.”

“This economic and focused approach to testing to detect and differentiate these infections replaces expensive syndromic panels or laboratories capable of performing high-complexity testing.”

Bryant further added that the easy-to-use molecular test does not require prior RNA extraction.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The ability of Solana to process up to 12 samples in a single 45-minute run is expected to offer time-saving and workflow advantages in moderately complex settings.

With CE-Mark obtained in August this year, the RSV + hMPV assay expands the firm’s Solana platform, which includes tests for the detection of various infections such as Clostridium difficile, Group A β-hemolytic Streptococcus, Herpes simplex virus 1 (HSV-1), influenza A and B, and trichomonas.